Carmot Therapeutics is a U.S.-based biotech company focused on developing incretin-based therapies, including CT-388 (a weekly injectable dual GLP-1/GIP agonist), an oral small-molecule GLP-1 agonist (CT-996), and another injectable GLP-1/GIP candidate (CT-868)
A recent survey from KFF shows that increasing numbers of employers are weighing whether to cover cutting-edge weight-loss medications
In particular, the Nlrp3 inflammasome is a cytosolic multiprotein complex expressed in immune/inflammatory cells as well as cardiovascular system cells, including endothelial cells, myofibroblasts/fibroblasts, and cardiomyocytes, which, through the processing and release of interleukin (IL)-1 and IL-18 and the induction of cell death processes (pyroptosis, apoptosis, and necroptosis), plays a key role in the maintenance of host homeostasis and in sustaining the pathophysiological events underlying CVDs (48)
New directions in incidence and prevalence of diagnosed diabetes in the USA